We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of C-type Natriuretic Peptide on Human Forearm Blood Vessels

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01075776
Recruitment Status : Withdrawn (Lack of funding)
First Posted : February 25, 2010
Last Update Posted : May 5, 2020
Sponsor:
Collaborator:
University College, London
Information provided by (Responsible Party):
Amrita Ahluwalia, Queen Mary University of London

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
To determine the effects of whether increasing CNP concentrations slightly above normal will improve the functioning of blood vessels after the interruption in the flow of blood. In this study we are looking at the function of the blood vessels of the forearm, as a substitute for those in the heart

Condition or disease Intervention/treatment Phase
Ischaemia-reperfusion (IR) Injury Drug: C-type natriuretic peptide (CNP) Drug: Saline Drug: Acetylcholine Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: The Effects of C-type Natriuretic Peptide on Endothelial Function Following Ischaemia-Reperfusion in the Human Forearm
Estimated Study Start Date : January 2020
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : January 2023
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: CNP
Infusion of CNP prior to IR injury
 Drug: C-type natriuretic peptide (CNP)
360 pmol/min for 15 minutes intra-arterially

Drug: Acetylcholine
2 stepped infusions for a total 9min per limb, totalling 1.05micromoles per limb
Placebo Comparator: Saline
Effect of saline infusion prior to IR injury
 Drug: Saline
Sodium Chloride 0.9% intra-arterially 0.5ml/min

Drug: Acetylcholine
2 stepped infusions for a total 9min per limb, totalling 1.05micromoles per limb


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in area under curve dose-response to acetylcholine after IR injury [ Time Frame: 2h ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy human volunteers on no systemic medication, excepting the oral contraceptive pill

Exclusion Criteria:

  • History of medical illness
  • Unwillingness to sign consent form
  • Use of non-OCP medications
  • Hypertension on examination of the blood pressure
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01075776


Locations
Layout table for location information
United Kingdom
Queen Mary University London
London, United Kingdom, EC1M 6BQ
Sponsors and Collaborators
Queen Mary University of London
University College, London
Investigators
Layout table for investigator information
Principal Investigator: Ahluwalia Amrita, BSc PhD Queen Mary University London
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Amrita Ahluwalia, Professor of Vascular Pharmacology, Queen Mary University of London
ClinicalTrials.gov Identifier: NCT01075776    
Other Study ID Numbers: 007143
First Posted: February 25, 2010    Key Record Dates
Last Update Posted: May 5, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Ischemia
Pathologic Processes
Natriuretic Peptide, C-Type
Acetylcholine
Vasodilator Agents
Cholinergic Agonists
 Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Natriuretic Agents